<DOC>
	<DOCNO>NCT02497053</DOCNO>
	<brief_summary>The prognosis mesothelioma generally poor . The median survival patient unresectable malignant mesothelioma range approximately 6-12 month . Survival poor curative treatment . Treatment option include surgery , chemotherapy radiotherapy . Recently multimodality treatment regimen report prolong survival . Other new therapeutic approach include immunotherapy , gene therapy , hyperthermic chemoperfusion pleura photodynamic therapy , result yet completely validate . Even introduction new therapeutic protocol , response exceed 41 % , mean survival 12 month . The current standard care unresectable malignant pleural mesothelioma pemetrexed/cisplatin . This regimen compare cisplatin alone study include 448 patient 19 country large trial date among patient suffer malignant mesothelioma . Results show statistically significant increase overall survival 30 % ( 12.1 month pemetrexed /cisplatin versus 9.3 month cisplatin alone . In addition , improvement lung function ( forced vital capacity ) pemetrexed /cisplatin arm comparison cisplatin arm . Until , however , consensus number cycle pemetrexed/cisplatin malignant mesothelioma approve predictive marker response . Pemetrexed/cisplatin regimen expensive regimen associate considerable toxicity need rationalize use Egyptian patient . Therefore , investigator aim work compare 4 cycle versus 6 cycle pemetrexed/cisplatin malignant mesothelioma identify predictive marker response .</brief_summary>
	<brief_title>Four Versus Six Cycles Pemetrexed/Platinum MPM</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologic cytologic diagnosis malignant pleural Mesothelioma 2 . No prior chemotherapy . 3 . ECOG le equal 2 . 4 . Measurable disease accord requirement SWOG criterion . 5 . Age ≥ 18 year . 6 . Estimated life expectancy least 12 week . 7 . Adequate bone marrow reserve ( white blood cell [ WBC ] ≥ 3.5 × 109 /L , neutrophils ≥ 1.5 × 109 /L , platelet ≥ 100 × 109 /L , hemoglobin ≥ 9.0 gm/dL ) . 1 . Presence central nervous system metastasis . 2 . Inadequate liver function ( bilirubin &gt; 1.5 time upper normal limit [ UNL ] alanine transaminase [ ALT ] aspartate transaminase [ AST ] &gt; 3.0 UNL 5.0 UNL presence hepatic metastasis ) . 3 . Inadequate renal function ( creatinine &gt; 1.25 time UNL , creatinine clearance &lt; 50mL/min ) . 4 . Serious concomitant systemic disorder incompatible study . 5 . Second primary malignancy ( except situ carcinoma cervix , adequately treat basal cell carcinoma skin , T1 vocal cord cancer remission , prior malignancy treat 5 year prior enrollment without recurrence ) . 6 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>MPM</keyword>
</DOC>